|
Objective: This experimental application of differential proteome detection of ovarian serous adenocarcinoma, ovarian serous cystadenoma protein spectrum, the further integration of bioinformatics method comparative analysis to filter out the differences between protein, thus looking for specific biomarkers . This experiment is only part of the ovarian cancer proteomics experiments last comparative analysis of the experimental results with the other five groups, the identification of an environment conducive to the early diagnosis of ovarian cancer-specific tumor markers. Methods: This study from ovarian serous cystadenocarcinoma tissue samples of ovarian serous cystadenoma two mixed samples, two experiments using two-dimensional liquid chromatography-mass spectrometry analysis technology, comprehensive two experimental results, ultimately ovarian serous adenocarcinoma, ovarian serous cystadenoma tissue differences in protein, the final protein determination based on difference of principle difference between the two proteins identified in ovarian serous adenocarcinoma and ovarian serous cystadenoma final. Results: 1. Using two-dimensional liquid chromatography-mass spectrometry analysis technique identified a total of 1085 proteins from ovarian serous adenocarcinoma samples, a total of 381 proteins were identified from samples of ovarian serous cystadenoma group. Protein determination based on difference of principle eventually identified ovarian serous adenocarcinoma, ovarian serous cystadenoma difference between the two groups a total of 128 proteins. 116 proteins were up-regulated in ovarian serous cystadenocarcinoma, 12 proteins were down-regulated. Wherein downward protein: the base film polysaccharide, collagen, a-3 (Ⅵ) 2,3,4 precursor the collagen XIV-A1 junction protein (DES), the histone H1 1-D chain, POTEE, decorin fibromodulin, PRELP, osteoinductive factor. Main difference between the two proteins in ovarian serous adenocarcinoma and ovarian serous cystadenoma, including components of the extracellular matrix, cytoskeletal component tumor immune-related proteins, and tumor material, energy metabolism related proteins, molecular companion, DNA repair genes, regulatory factors (growth factors, growth factor receptors, signal transduction proteins, transcription factors), and abnormal protein associated with tumor cell apoptosis, signal transduction related proteins and other ovarian cancer development , invasion and metastasis-related protein. Conclusion: 1. Experiments identified differentially expressed proteins in ovarian serous adenocarcinoma and ovarian serous cystadenoma, which many protein expression in ovarian serous cystadenocarcinoma exception for the first time reported. These proteins will be conducive to the differential diagnosis of ovarian serous cystadenocarcinoma and ovarian serous cystadenoma. The comparative analysis of the experimental results with the other five groups, the final identification of valuable tumor marker for early diagnosis of ovarian cancer. 2. Tumor material and energy metabolism abnormalities associated protein which can be used for the establishment of the diagnosis of ovarian cancer metabolomics recognition mode
|